/ 1 min read

Reed Smith advises Logiprem-F on its sale to Evolucare Technologies

PARIS — The Paris office of Reed Smith advised the shareholders of Logiprem-F on the sale of 100% of the company’s share capital and voting rights to Evolucare Technologies, the French subsidiary of the Italian group GPI, a specialist in software solutions for the healthcare sector. Simultaneously, an 11% stake was transferred to Logiprem-F's top managers, bringing Evolucare Technologies' participation to 89% of the share capital.

Since 2016, Logiprem-F has developed Logipren, a SaaS platform that supports medication prescription processes for neonatal and paediatric intensive care units. A market leader in France in this segment, the company now supports more than 90 hospitals and has a team of around 40 employees, helping secure the entire prescription and administration pathway for newborns and young patients.

This transaction forms part of Evolucare and the GPI group’s strategy to strengthen their “critical care” division and consolidate their position as a leading European provider of critical care software, particularly in France and across major European markets.

Reed Smith acted as legal counsel to the shareholders of Logiprem-F on the corporate aspects of the transaction. The team included Marc Fredj (partner), Antea Bonito (associate), and Camille Diz (legal counsel).

The buyer, Evolucare Technologies, was advised by GWL Avocats, led by Siham Belarbi (partner).

About Reed Smith

Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. With an inclusive culture and innovative mindset, we deliver smarter, more creative legal services that drive better outcomes for our clients. Our deep industry knowledge, long-standing relationships, and collaborative structure make us the go-to partner for complex disputes, transactions, and regulatory matters.

For more information, please visit reedsmith.com.

Related news

Related Insights